SureTrader Advertisement PRTC
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 5/20/2016 2:10:53 PM - Followers: 168 - Board type: Free - Posts Today: 0


Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The Bioheart Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
BHRT - Daily Candlesticks


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
USRM News: Statement of Ownership (sc 13g) 05/26/2016 11:42:40 AM
USRM News: Quarterly Report (10-q) 05/04/2016 04:05:37 PM
USRM News: Statement of Ownership (sc 13g) 04/28/2016 04:39:00 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 02/16/2016 04:06:55 PM
USRM News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 02/16/2016 04:04:22 PM
#17027   4.5 CENTS, ANOTHER new, all, all TIME LOW Hornet Driver 05/20/16 02:10:52 PM
#17026   Dilution has been STAGGERING, still on-going: Hornet Driver 05/13/16 01:55:05 PM
#17025   Correction: Got the timing wrong. The number of common Poor Man - 05/08/16 10:00:23 PM
#17024   "As of May 4, 2016, there were 5,042,656 Poor Man - 05/05/16 05:57:05 PM
#17023   U.S. Stem Cell, Inc. Reports Positive Results for Investaholic33 05/05/16 05:08:13 PM
#17022   This company is a POS garym 05/04/16 09:06:25 AM
#17021   SEC 13G shows MASSIVE on-going DILUTION: Hornet Driver 04/30/16 09:49:01 PM
#17020 EquityElite 04/21/16 07:45:46 AM
#17019   Hmm it has been a while... too long. Investaholic33 04/20/16 09:49:18 PM
#17018   Blog is out? EquityElite 04/20/16 03:54:04 PM
#17017   5 CENTS, ANOTHER RECORD ALL, ALL TIME LOW ! Hornet Driver 04/18/16 10:49:53 AM
#17016   Mr Tomas should be in jail for what toddski 04/11/16 08:42:26 PM
#17015   9 CENTS, ANOTHER record ALL, ALL TIME LOW ! Hornet Driver 04/11/16 02:43:36 PM
#17014   How are the CD lenders doing on this? EquityElite 04/11/16 11:42:34 AM
#17013   This scam should be shut down and the Ringohalfcan 03/31/16 02:18:52 PM
#17012   Selling shares to the end. With no Ringohalfcan 03/31/16 02:06:12 PM
#17011   Yes aaaaaannnyyyyttthhing andyshow 03/28/16 03:27:22 PM
#17010   Wish we would hear aaannyyything from the company. Investaholic33 03/23/16 09:59:14 PM
#17009   .12 52W low? EquityElite 03/23/16 09:29:03 PM
#17008   17 CENTS, another NEW ALL TIME LOW TODAY Hornet Driver 03/21/16 11:01:36 PM
#17007   What's happening ? EquityElite 03/16/16 08:51:31 PM
#17006   U.S. Stem Cell reported $3.9 million in aggregate Poor Man - 03/12/16 12:07:12 AM
#17005   What a dog of a stock Poor Man - 03/10/16 07:38:41 PM
#17004   Bid at 15 CENTS, uh oh???? Hornet Driver 03/10/16 01:21:05 PM
#17003   NEW lawsuit, Roche Diagnostics sues U.S. Stem Cell Hornet Driver 03/08/16 10:55:50 PM
#17000   Those links are bogus- it's a "scraper" website Hornet Driver 03/02/16 11:15:42 AM
#16999 JWMN 03/02/16 09:52:13 AM
#16998 JWMN 03/02/16 09:50:54 AM
#16997   .2086 = new ALL ALL TIME LOW, LOL ! Hornet Driver 03/01/16 04:32:12 PM
#16996   This stock is like a sewer drain. Poor Man - 02/26/16 07:08:39 PM
#16995   .22 LOW, gawd what a POS, LOL !!! Hornet Driver 02/26/16 03:27:01 PM
#16994   Up 53% ??? what is going on with ihubmoney 02/25/16 09:41:09 AM
#16993   If I submitted my recipe for Cocktail Sauce, Poor Man - 02/24/16 06:17:23 PM
#16992 Kristin Comella JWMN 02/24/16 04:07:50 PM
#16991   Worst Stock of the Year - USRM Poor Man - 02/22/16 10:30:21 PM
#16990   FALLING ! .26, w/ .25 Bid, HOLY COW !!! Hornet Driver 02/22/16 02:16:43 PM
#16989   LOL toddski 02/18/16 08:15:34 PM
#16988   Do you think his will bounce back over $1-$3? EquityElite 02/18/16 04:59:40 PM
#16987   $USRM WOW back to 0.50's...:-} captainscotty 02/17/16 07:28:26 PM
#16986   LAUGH OUT LOUD!!! Poor Man - 02/16/16 10:53:15 AM
#16985   New SEC filing, FINALLY LOL !!! Hornet Driver 02/16/16 09:50:46 AM
#16984   Murphy is like 93+ years old.... Poor Man - 02/10/16 08:07:05 PM
#16983   Dr Murphy JWMN 02/10/16 01:50:31 PM
#16982   PPS? EquityElite 02/10/16 12:36:34 PM
#16981   $USRM What happened here Cap Kirk,,,TRAIN WRECK...:-{ captainscotty 02/09/16 07:28:46 PM
#16980   ONE HUNDRED PERCENT SPREAD, LOL??????? Hornet Driver 02/08/16 02:29:01 PM
#16979   Everybody is Losing Their F'n Shirts... Poor Man - 02/06/16 01:39:09 PM
#16978   And yet they have the audacity for paying toddski 02/05/16 01:21:42 PM
#16977   .26, Going DOWN IN FLAMES, LOL !! Hornet Driver 02/05/16 10:46:32 AM
#16976   Headed to Zero Poor Man - 02/04/16 08:46:35 PM